On Monday, Enliven Therapeutics Inc (NASDAQ: ELVN) opened lower -6.60% from the last session, before settling in for the closing price of $21.07. Price fluctuations for ELVN have ranged from $15.96 to $30.03 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -16.22% at the time writing. With a float of $31.69 million, this company’s outstanding shares have now reached $48.94 million.
The extent of productivity of a business whose workforce counts for 62 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Enliven Therapeutics Inc (ELVN) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Enliven Therapeutics Inc is 35.34%, while institutional ownership is 72.82%. The most recent insider transaction that took place on Mar 27 ’25, was worth 69,321. In this transaction CHIEF FINANCIAL OFFICER of this company sold 3,250 shares at a rate of $21.33, taking the stock ownership to the 23,000 shares. Before that another transaction happened on Mar 27 ’25, when Company’s Officer proposed sale 4,250 for $20.58, making the entire transaction worth $87,465.
Enliven Therapeutics Inc (ELVN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -18.00% during the next five years compared to 19.02% growth over the previous five years of trading.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
Check out the current performance indicators for Enliven Therapeutics Inc (ELVN). In the past quarter, the stock posted a quick ratio of 19.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -2.54 in one year’s time.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
The latest stats from [Enliven Therapeutics Inc, ELVN] show that its last 5-days average volume of 0.3 million was superior to 0.24 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 32.74%. Additionally, its Average True Range was 1.25.
During the past 100 days, Enliven Therapeutics Inc’s (ELVN) raw stochastic average was set at 9.09%, which indicates a significant increase from 6.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.93% in the past 14 days, which was higher than the 54.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.24, while its 200-day Moving Average is $23.47. Now, the first resistance to watch is $20.73. This is followed by the second major resistance level at $21.79. The third major resistance level sits at $22.41. If the price goes on to break the first support level at $19.05, it is likely to go to the next support level at $18.43. Assuming the price breaks the second support level, the third support level stands at $17.37.
Enliven Therapeutics Inc (NASDAQ: ELVN) Key Stats
There are currently 49,004K shares outstanding in the company with a market cap of 964.41 million. Presently, the company’s annual sales total 0 K according to its annual income of -89,020 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -23,180 K.
